RAPT Therapeutics, Inc. (RAPT) NASDAQ

58.01

+0.0000011(+0.00%)

Updated at March 06 09:30AM

Currency In USD

RAPT Therapeutics, Inc.

Address

561 Eccles Avenue

South San Francisco, CA 94080

United States of America (the)

Phone

650 489 9000

Sector

Healthcare

Industry

Biotechnology

Employees

67

First IPO Date

October 31, 2019

Key Executives

NameTitlePayYear Born
Brian Russell WongChief Executive Officer, President & Director1.05M1971
Dirk G. BrockstedtChief Scientific Officer490,2501969
WilliamChief Medical Officer709,5821965
Rodney K. YoungChief Financial Officer, Principal Accounting Officer & Secretary716,0041963
Nipun DavarSenior Vice President of Technical Operations01968
Paul KassnerSenior Vice President of Biology01967
Michael ListgartenGeneral Counsel0N/A
Gwen R. CarscaddenChief Human Resources Officer01961
Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality Assurance0N/A
Steve YoungVice President of Technology0N/A

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.